Recce Pharmaceuticals — Gearing up for more R327 studies

Recce Pharmaceuticals (ASX:RCE) kicks off phase I/II UTI trial

Recce Pharmaceuticals lands ethics approval for expanded UTI studies

Recce Pharmaceuticals receives Ethics Approval to expand R327 Faster Infusion, Phase I/II Clinical Trial

Recce Pharmaceuticals (ASX:RCE) gains ethics approval to expand phase I/II trial of R327

Recce Pharmaceuticals recruits outpatient nurses to drive “largest in Australia” diabetic foot infection clinical trial

Recce Pharmaceuticals (ASX:RCE) appoints outpatient nurses from Ascott

Recce Pharmaceuticals (ASX:RCE) secures sponsorship to attend BIO Korea 2023

ASX:RCE

Recce Pharmaceuticals Ltd attracts $1.8 million as it moves toward human clinical trials Recce Pharmaceuticals Ltd (ASX:RCE) has raised about $1.8 million from sophisticated and institutional investors…

Recce Pharmaceuticals locks

In US patent for synthetic antibiotic to target growing superbug problem Recce Pharmaceuticals (ASX: RCE) has locked-in a US patent for its broad-spectrum synthetic antibiotics, paving the way for the…